As the most common inflammatory arthritis among men, gout is an inconsistent condition. Gout may remit for long periods, present as flare-ups for days or weeks, or be chronic for months or longer. The advent of Febuxostat CAS# 144060-53-7, has offered hope to patients with this debilitating form of arthritis. As an effectual treatment for gout, Febuxostat is in a class of medications deemed xanthine oxidase inhibitors. By decreasing the amount of uric acid that is made in the body Febuxostat helps to prevent gout attacks, but it will not treat acute attacks once they occur. As a type of arthritis wherein uric acid builds up in the joints, causing sudden attacks of pain, redness and swelling in one or more joints, gout is often a disabling condition for patients. Gout has caused hyperuricemia, which is an uncontrolled metabolic disorder. Besides hyperuricemia, risk factors for gout also include hypertension, obesity, alcohol intake, a diet rich in meat and seafood and the use of diuretics.
Allopurinol is most frequently prescribed to treat patients with gout in the United States, but the majority of patients treated with allopurinol do not typically achieve their target serum uric acid levels. Many patients cannot tolerate doses in excess of 300 milligrams of allopurinol due to renal insufficiency. Febuxostat, approved by the FDA in 2009 for the chronic management of hyperuricemia in patients with gout, has offered a new avenue of treatment options for these patients. Patients in clinical trials who received Febuxostat achieved a rapid and significant reduction in their serum uric acid levels. When compared with patients who were dosed with allopurinol, the patients who received 80 milligrams daily of Febuxostat were more likely to achieve serum uric acid concentrations less than 6 mg/dl. Long-term studies of Febuxostat have gleaned positive and consistent results as well. In a five year period the patients who were dosed with Febuxostat demonstrated sustained reductions in their serum uric acid levels and experienced an almost complete elimination of gout flares-ups. Adverse effects of Febuxostat were also reported to be less severe and occur less often when compared with Allopurinol. Commonly reported adverse effects included a rash, nausea, and liver function abnormalities. The recommended starting dose of Febuxostat is 40 milligrams daily, with a slow increase to 80 milligrams daily if needed over a two week period.
The international prevalence of gout is 0.3 percent, but the statistics are varied based on each country. Gout is more predominant in males, as prevalence of gout is 13.6 cases per 1000 men as compared to 6.4 cases per 1000 women. With the average life span being extended worldwide, as well as the rise in obesity and comorbid health conditions, the rise is patients with gout is sure to occur. LGM Pharma provides API Febuxostat for research and development purposes.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.